Verastem Reports $25.1M in Q2 Revenue Amid Anticipation for Oncology Trial Results

Key Facts

1Verastem achieved net product revenues of $25.1M in Q2 2026 during the fourth quarter of its Co-pack launch.

2Markets are awaiting the October readout from the TARGET-D 101 trial of VS-7375 in solid tumors.

Verastem achieved net product revenues of $25.1 million in the second quarter of 2026. Seeking Alpha reported that these results occurred during the fourth quarter of the company's Avmapki Fakzynja Co-pack launch as it transitions into a commercial-stage biotech firm.

Markets are currently awaiting the October readout from the TARGET-D 101 trial of VS-7375 in solid tumors. VSTM closed at $8 on October 5, 2026, with the stock reaching a day high of $8.1 and a low of $7.52 during that session.